Ledipasvir/Sofosbuvir, Gilead Sciences

Drug: Ledipasvir/Sofosbuvir
Company: Gilead Sciences
Phase: Filed
Class: Hepatitis C nucleoside NS5A & NS5B polymerase inhibitor
2020 sales: $2.8 billion
Net present value: $9.8 billion

Whatever else is going on at the company, Gilead ($GILD) knows how to make money with new drugs. Loved for its innovation, hated for its pricing, Gilead steamrolled ahead with Sovaldi (sofosbuvir) through the clinic and right into the biggest drug launch of all time. Now comes the first combo for hepatitis C, the next step in a new generation of cocktail therapies that are eradicating the former mainstays in the disease and making it possible for a wide swathe of patients to complete the cure. Gilead grew rhino-thick skin developing the HIV market and it promises to continue its damn-the-torpedoes-full-speed-ahead philosophy in hep C.

For more:
AbbVie heads to the FDA with its hep C combo in a race with Gilead, Merck
Gilead hands its hep C combo to the FDA as AbbVie race heats up
Gilead scrambles toward hep C cure-all with next-gen combo pill

Ledipasvir/Sofosbuvir, Gilead Sciences
Read more on

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.